Integra LifeSciences Holdings Corporation (NASDAQ:IART) Director Barbara B. Hill bought 10,768 shares of the stock in a transaction dated Tuesday, October 31st. The shares were purchased at an average cost of $46.66 per share, for a total transaction of $502,434.88. Following the completion of the purchase, the director now owns 55,540 shares in the company, valued at $2,591,496.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its quarterly earnings data on Thursday, October 26th. The life sciences company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.02). The firm had revenue of $278.83 million during the quarter, compared to analyst estimates of $286.00 million. Integra LifeSciences Holdings Corporation had a net margin of 4.52% and a return on equity of 16.35%. The business’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.93 EPS.

COPYRIGHT VIOLATION WARNING: “Insider Buying: Integra LifeSciences Holdings Corporation (IART) Director Purchases 10,768 Shares of Stock” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/11/01/insider-buying-integra-lifesciences-holdings-corporation-iart-director-purchases-10768-shares-of-stock.html.

Hedge funds have recently modified their holdings of the stock. Eagle Asset Management Inc. increased its position in Integra LifeSciences Holdings Corporation by 39.0% during the second quarter. Eagle Asset Management Inc. now owns 1,647,018 shares of the life sciences company’s stock worth $89,778,000 after purchasing an additional 461,977 shares during the last quarter. Strs Ohio increased its position in Integra LifeSciences Holdings Corporation by 60.4% during the second quarter. Strs Ohio now owns 7,700 shares of the life sciences company’s stock worth $419,000 after purchasing an additional 2,900 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in Integra LifeSciences Holdings Corporation by 116.8% during the first quarter. Schwab Charles Investment Management Inc. now owns 244,982 shares of the life sciences company’s stock worth $10,322,000 after purchasing an additional 131,995 shares during the last quarter. Jennison Associates LLC increased its position in Integra LifeSciences Holdings Corporation by 12.3% during the second quarter. Jennison Associates LLC now owns 697,772 shares of the life sciences company’s stock worth $38,036,000 after purchasing an additional 76,548 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its position in Integra LifeSciences Holdings Corporation by 80.1% during the second quarter. State of Alaska Department of Revenue now owns 11,939 shares of the life sciences company’s stock worth $650,000 after purchasing an additional 5,309 shares during the last quarter. 84.88% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have recently issued reports on IART shares. Zacks Investment Research raised shares of Integra LifeSciences Holdings Corporation from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research note on Tuesday, October 10th. Cantor Fitzgerald set a $65.00 target price on shares of Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a research note on Wednesday, July 26th. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research note on Wednesday, July 26th. Jefferies Group LLC reissued a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research note on Sunday, September 10th. Finally, UBS AG reissued a “buy” rating and set a $57.00 target price on shares of Integra LifeSciences Holdings Corporation in a research note on Tuesday. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Integra LifeSciences Holdings Corporation has a consensus rating of “Buy” and an average target price of $53.64.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Insider Buying and Selling by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.